hMTR4-PDIA3P1-miR-125/124-TRAF6调控轴在NF-κB信号与化疗耐药中的作用
本研究探讨lncRNA PDIA3P1在肿瘤化疗耐药中的作用。PDIA3P1在多种癌症中上调,其高表达与肝细胞癌无复发生存期较差相关。机制上,PDIA3P1作为miRNA海绵吸附miR-125a/b和miR-124,解除对TRAF6的抑制,激活NF-κB通路,从而介导多柔比星耐药;hMTR4可结合并降解PDIA3P1,而多柔比星处理破坏该相互作用。
要点
- PDIA3P1高表达与肝细胞癌无复发生存期较差相关。
- PDIA3P1通过吸附miR-125a/b和miR-124上调TRAF6,激活NF-κB。
- hMTR4介导PDIA3P1降解,多柔比星处理破坏该相互作用。
核心结论
- 存在hMTR4-PDIA3P1-miR-125/124-TRAF6调控轴,调控NF-κB信号和化疗耐药,可能用于抗癌治疗。
研究设计与样本
- 基础研究,涉及多种癌症类型细胞实验、小鼠异种移植瘤实验及人肝细胞癌组织分析。
主要发现
- PDIA3P1在多种癌症类型中上调,并在DNA损伤性化疗药如多柔比星处理后上调。
- PDIA3P1高表达与肝细胞癌患者无复发生存期较差相关。
- PDIA3P1保护癌细胞免受多柔比星诱导的凋亡,使异种移植瘤生长更快且对多柔比星治疗更耐药。
- miR-125a/b和miR-124抑制TRAF6表达,PDIA3P1结合这些miRNA并解除其对TRAF6的抑制,激活NF-κB通路。
- NF-κB抑制剂BAY 11-7085可减轻PDIA3P1诱导的小鼠异种移植瘤对多柔比星的耐药。
临床怎么用
- PDIA3P1高表达可能提示肝细胞癌患者无复发生存期较差。
- 靶向PDIA3P1或NF-κB通路可能逆转PDIA3P1介导的化疗耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: DNA damage-induced NF-κB activation is a major obstacle to effective antitumour chemotherapy. Long noncoding RNAs (lncRNAs) that regulate chemoresistance of cancer cells remain largely unknown. This study aimed to characterize the lncRNAs that may affect chemotherapy sensitivity. APPROACH AND RESULTS: We found that lncRNA PDIA3P1 (protein disulfide isomerase family A member 3 pseudogene 1) was up-regulated in multiple cancer types and following treatment with DNA-damaging chemotherapeutic agents, like doxorubicin (Dox). Higher PDIA3P1 level was associated with poorer recurrence-free survival of human hepatocellular carcinoma (HCC). Both gain-of-function and loss-of-function studies revealed that PDIA3P1 protected cancer cells from Dox-induced apoptosis and allowed tumor xenografts to grow faster and to be more resistant to Dox treatment. Mechanistically, miR-125a/b and miR-124 suppressed the expression of tumor necrosis factor receptor-associated factor 6 (TRAF6), but PDIA3P1 bound to miR-125a/b/miR-124 and relieved their repression on TRAF6, leading to activation of the nuclear factor kappa B (NF-κB) pathway. Consistently, the effect of PDIA3P1 inhibition in promoting Dox-triggered apoptosis was antagonized by silencing the inhibitor of κBα (IκBα) or overexpressing TRAF6. Administration of BAY 11-7085, an NF-κB inhibitor attenuated PDIA3P1-induced resistance to Dox treatment in mouse xenografts. Moreover, up-regulation of PDIA3P1 was significantly correlated with elevation of TRAF6, phosphorylated p65, or NF-κB downstream anti-apoptosis genes in human HCC tissues. These data indicate that enhanced PDIA3P1 expression may confer chemoresistance by acting as a microRNA sponge to increase TRAF6 expression and augment NF-κB signaling. Subsequent investigations into the mechanisms of PDIA3P1 up-regulation revealed that human homologue of mRNA transport mutant 4 (hMTR4), which promotes RNA degradation, could bind to PDIA3P1, and this interaction was disrupted by Dox treatment. Overexpression of hMTR4 attenuated Dox-induced elevation of PDIA3P1, whereas silencing hMTR4 increased PDIA3P1 level, suggesting that Dox may up-regulate PDIA3P1 by abrogating the hMTR4-mediated PDIA3P1 degradation. CONCLUSION: There exists a hMTR4-PDIA3P1-miR-125/124-TRAF6 regulatory axis that regulates NF-κB signaling and chemoresistance, which may be exploited for anticancer therapy.
引用
- Xie C, Zhang LZ, Chen ZL, et al. A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance. Hepatology. 2019. PMID: 31509261. doi:10.1002/hep.30931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。